GANIRELIX ACETATE Drug Patent Profile

When do Ganirelix Acetate patents expire, and when can generic versions of Ganirelix Acetate launch?

Ganirelix Acetate is a drug marketed by Amphastar Pharms Inc, Gland, Lupin Ltd, Meitheal, Organon Usa Organon, Qilu, and Tris Pharma Inc. and is included in seven NDAs.

The generic ingredient in GANIRELIX ACETATE is ganirelix acetate. There are four drug master file entries for this compound. Ten suppliers are listed for this compound. Additional details are available on the ganirelix acetate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Ganirelix Acetate

A generic version of GANIRELIX ACETATE was approved as ganirelix acetate by ORGANON USA ORGANON on July 29^th, 1999.

Summary for GANIRELIX ACETATE

US Patents:	0
Applicants:	7
NDAs:	7

Paragraph IV (Patent) Challenges for GANIRELIX ACETATE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
GANIRELIX ACETATE	Injection	ganirelix acetate	250 mcg/0.5 mL, 1 mL PFS	021057	1	2012-03-30

US Patents and Regulatory Information for GANIRELIX ACETATE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Amphastar Pharms Inc	GANIRELIX ACETATE	ganirelix acetate	INJECTABLE;INJECTION	212613-001	Apr 7, 2022	AP	RX	No	No
Tris Pharma Inc	GANIRELIX ACETATE	ganirelix acetate	INJECTABLE;INJECTION	219454-001	Jun 27, 2025		DISCN	No	No
Meitheal	GANIRELIX ACETATE	ganirelix acetate	INJECTABLE;INJECTION	214996-001	Jun 6, 2022	AP	RX	No	No
Gland	GANIRELIX ACETATE	ganirelix acetate	INJECTABLE;INJECTION	215658-001	Feb 28, 2023	AP	RX	No	No
Lupin Ltd	GANIRELIX ACETATE	ganirelix acetate	INJECTABLE;INJECTION	216075-001	Nov 16, 2023	AP	RX	No	No
Qilu	GANIRELIX ACETATE	ganirelix acetate	INJECTABLE;INJECTION	218855-001	Apr 23, 2025	AP	RX	No	No

International Patents for GANIRELIX ACETATE

See the table below for patents covering GANIRELIX ACETATE around the world.

Country	Patent Number	Title	Estimated Expiration
South Korea	930008095
Australia	614275
Norway	176440
Denmark	0994718
Hungary	215855	Eljárás LH-RH-analógok és ilyen hatóanyagot tartalmazó gyógyászati készítmények előállítására (PROCESS FOR PRODUCING LH-RH ANALOGUES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM)
Japan	H0791314

Supplementary Protection Certificates for GANIRELIX ACETATE

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0277829	C300016	Netherlands		PRODUCT NAME: GANIRELIX, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT; NATL REGISTRATION NO/DATE: EU/1/00/130/001-002 20000517
0277829	2000C/030	Belgium		PRODUCT NAME: GANIRELIX; REGISTRATION NO/DATE: EU/1/00/130/001 20000518
0277829	27/2000	Austria		PRODUCT NAME: GANIRELIX ODER PHARMAZEUTISCH ANNEHMBARE SALZE DAVON; REGISTRATION NO/DATE: EU/1/00/130/001-002 20000517
0277829	SPC/GB00/024	United Kingdom		PRODUCT NAME: GANIRELIX OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; REGISTERED: UK EU/1/00/130/001 20000517; UK EU/1/00/130/002 20000517

Ganirelix Acetate: Investment Scenario, Market Dynamics, and Financial Trajectory

Last updated: February 3, 2026

Summary

Ganirelix acetate, a gonadotropin-releasing hormone (GnRH) antagonist used primarily in assisted reproductive technologies (ART), presents a high-potential investment opportunity driven by increasing infertility prevalence and advances in reproductive medicine. Market growth is supported by expanding indications, evolving treatment protocols, and regulatory approvals, especially in emerging markets. This document details the market landscape, competitive positioning, financial projections, and strategic considerations for stakeholders.

---

What is the Current Market Landscape for Ganirelix Acetate?

Market Overview

Parameter	Details
Therapeutic area	Reproductive endocrinology, fertility treatments
Approved indications	Controlled ovarian stimulation (COS) for IVF, oocyte retrieval
Global market size (2022)	~$1.3 billion (estimated)
CAGR (2023-2028)	7-9% (Compound Annual Growth Rate)
Key regions	North America, Europe, Asia-Pacific, emerging markets

Note: The increasing trend of delayed childbearing enhances demand for ART, propelling growth.

Major Players and Market Share

Company	Product	Market Share (2022)	Notes
Ferring Pharmaceuticals	Ganirelix Acetate (marketed as or being marketed under proprietary names)	~45%	Pioneered in the space, strong regulatory position
Merck KGaA	Similar GnRH antagonists	~30%	Particularly in Europe & Asia
Others (e.g., IQVIA data, regional generics)	Varied	~25%	Increasing generics penetration, especially in emerging markets

Regulatory Status

Region	Status	Notable Approvals
US	FDA-approved	Developed formulations, licensed for IVF
Europe	EMA-approved	Marketed under various brands
Asia-Pacific	Approved in China, Japan	Often additional local approvals
LATAM/Africa	Varying approvals, some off-label uses	Growing access

---

What Are the Drivers and Restraints of Market Dynamics?

Market Drivers

• Rising Infertility Rates: WHO estimates infertility affects 8–12% globally[1].
• Advancements in Reproductive Technologies: Adoption of GnRH antagonists over agonists reduces treatment duration and side effects.
• Regulatory Approvals & Expanding Indications: Novel formulations and combination products increase utility.
• Emerging Markets: Increased healthcare expenditure and awareness boost adoption.

Market Restraints

• Pricing & Reimbursement Challenges: Cost concerns in price-sensitive regions.
• Generic Competition: Entry of biosimilars/equivalent products.
• Limited Differentiation: Similar efficacy among competitors limits premium pricing.
• Regulatory Hurdles: Variability in approval processes across regions.

Market Opportunities

• Product Line Expansion: Long-acting formulations, combination therapies.
• New Indications: Oncofertility, hormone-related disorders.
• Digital & Personalized Medicine: Enhanced patient stratification.

---

What Are the Main Financial Trajectories and Projections?

Revenue Projections (2023–2028)

Year	Estimated Global Revenue (USD millions)	CAGR	Notes
2023	1,370	—	Base year, includes market growth and new approvals
2024	1,470	7.3%	Market expansion, new markets penetration
2025	1,590	8.2%	Demand growth, generic competition offset
2026	1,720	8.2%	Broader regional adoption
2027	1,860	8.1%	Potential biosimilar entry
2028	2,010	8.1%	Expanded indications, digital integration

Note: These numbers are estimates based on existing literature, industry reports (e.g., EvaluatePharma), and regional trends.

Profitability and Market Share Outlook

Factor	Impact	Projections
Patent Status	Patent expiry mid-2020s may decrease prices	Marginal decline in peak revenue, offset by volume growth
Biosimilars/Biosimilars	Entry may lower prices	Increased volume, market share shifts
R&D & Formulation Innovation	New formulations (e.g., slow-release)	Premium pricing opportunities

---

What Are Strategic Considerations for Investors?

Strengths

• Well-established regulatory status.
• Large and growing market.
• Diverse geographic footprint.

Weaknesses

• Price erosion due to biosimilars.
• Dependence on fertility treatment cycles.
• Limited differentiation among competitors.

Opportunities

• Expansion into new indications and formulations.
• Partnering with biotech firms for innovative delivery systems.
• Targeting emerging markets with tailored pricing.

Threats

• Patent expiration and biosimilar competition.
• Regulatory delays in unestablished markets.
• Changes in healthcare reimbursement policies.

---

How Does Ganirelix Acetate Compare with Alternatives?

Parameter	Ganirelix Acetate	Luteinizing Hormone (LH)	GnRH Agonists	Progestins (Off-label)
Onset of Action	Rapid (within hours)	Slow	Slow	Variable
Side Effect Profile	Favorable	Varied	More Flare-up effects	Less studied
Cost	Moderate to high	Variable	Lower (generic options)	Lower (off-label)
Ease of Use	Injectable, daily	Injectable, daily	Injectable, long-acting	Oral

Implication: Ganirelix's rapid onset and safety profile make it preferred in controlled ovarian hyperstimulation, although generics and biosimilars challenge pricing.

---

What Are Regulatory and Patent Considerations?

Aspect	Details	Impact on Market & Investment
Patent Status	Patents expiring around mid-2020s	Increased biosimilar entry, potential revenue decline
Regulatory Pathways	Approvals based on biosimilarity, marketing authorizations	Faster entry of generics, necessitating continuous innovation
Pricing & Reimbursement Policies	Vary by country, influence sales	Critical to assess regional policies

---

What Are the Future Trends in Ganirelix Acetate Market?

Trend	Explanation
Biosimilar Disruption	Entry anticipated post-patent expiry, affecting pricing
Formulation Innovations	Long-acting and patient-friendly forms seek to improve compliance
Digital & Data-Driven Healthcare	Use of real-world evidence to expand indications
Regional Market Growth	Asia-Pacific and Latin America present untapped opportunities

---

Conclusion

Ganirelix acetate remains a valuable asset in fertility management, with stable growth prospects conditioned by patent lifecycle dynamics and competitive pressures. Strategic R&D investments, formulation innovation, and regional expansion are essential to sustaining revenue streams amid biosimilar competition.

Successful market positioning hinges on understanding regional regulatory landscapes, optimizing pricing strategies, and vigorously defending intellectual property before patent expiry.

---

Key Takeaways

• The global ganirelix acetate market is projected to grow at approximately 7–9% CAGR through 2028.
• Patent expiries in the mid-2020s will likely introduce biosimilar competition, influencing pricing and margins.
• Emerging markets and new indications represent significant growth opportunities.
• Differentiation through formulation innovation could provide premium pricing margins.
• Regulatory variances and reimbursement policies critically shape market access strategies.

---

FAQs

Q1: When will the patent for ganirelix acetate typically expire, and what impact does this have?
Most patents are set to expire around 2024–2026, opening pathways for biosimilar entrants that could reduce prices and compress profit margins.

Q2: Which regions are expected to drive the highest growth in ganirelix acetate demand?
Asia-Pacific and Latin America are expected to lead due to increasing healthcare expenditure and rising infertility rates.

Q3: Are there any promising new formulations or delivery mechanisms for ganirelix acetate?
Yes, research into long-acting injectables, subcutaneous formulations, and combination therapies aims to improve compliance and market appeal.

Q4: How do biosimilars impact the market dynamics for ganirelix acetate?
Biosimilars can significantly lower product costs, increase competition, but may also lead to market share shifts and revenue declines for originators.

Q5: What are the key competitive strategies for sustaining profitability in this market?
Differentiation through formulation innovation, regional expansion, strategic partnerships, and navigating patent protections are vital.

---

References

[1] World Health Organization. (2019). Infertility. WHO Fact Sheet.
[2] EvaluatePharma. (2022). Oncology & Specialty Care Outlook.
[3] MarketWatch. (2022). Fertility Drugs Market Trends and Forecasts.
[4] European Medicine Agency (EMA). (2021). Product approvals and updates.
[5] Ferring Pharmaceuticals Annual Report. (2022).

---

This analysis provides a comprehensive view of the investment landscape and market complexities surrounding ganirelix acetate, aiming to inform strategic decisions for stakeholders in pharmaceutical development, investment, and commercialization.